Chuck Royce's BBOT Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 384,941 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) worth $2.93 M, representing 0.02% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Chuck Royce has initiated a new position in BBOT, representing a fresh investment thesis on this company. Largest reduction occurred in Q2 2026, reducing 251,581 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's BridgeBio Oncology Therapeutics (BBOT) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Oncology Therapeutics (BBOT) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -251,581 | Reduce 39.52% | 384,941 | $7.62 |
| Q1 2026 | +636,522 | New Buy | 636,522 | $8.95 |
Chuck Royce's BridgeBio Oncology Therapeutics Investment FAQs
Chuck Royce first purchased BridgeBio Oncology Therapeutics, Inc. (BBOT) in Q1 2026, acquiring 636,522 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held BridgeBio Oncology Therapeutics, Inc. (BBOT) for 2 quarters since Q1 2026.
Chuck Royce's largest addition to BridgeBio Oncology Therapeutics, Inc. (BBOT) was in Q1 2026, adding 636,522 shares worth $5.7 M.
According to the latest 13F filing for Q2 2026, Chuck Royce's firm, Royce & Associates Lp, owns 384,941 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT), valued at approximately $2.93 M.
As of the Q2 2026 filing, BridgeBio Oncology Therapeutics, Inc. (BBOT) represents approximately 0.02% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in BridgeBio Oncology Therapeutics, Inc. (BBOT) was 636,522 shares, as reported at the end of Q1 2026.